Structure Therapeutics and POINT Biopharma in the spotlight

Updates and future outlook on $GPCR and $PNT, including $LNTH in the context of Novartis and Lilly

Yesterday, both obesity and radiopharmaceuticals had year-end catalysts that unfortunately did not meet investor expectations.

Structure ($GPCR) Weight Loss Update
$GPCR traded down 42% on the Phase 1/2 update of SBR-1290, the company’s oral weight loss.

In the type 2 diabetes mellitus (T2DM) cohort, SBR-1290 demonstrated a statistically significant reduc…